First Patient Safety

Hemogenyx Pharmaceuticals plc is pleased to announce that the first patient has been successfully treated as part of the Company's Phase I clinical trial of HG-CT-1, the Company's proprietary CAR-T cell therapy for relapsed or refractory acute myeloid leukemia (R/R AML) in adults. The treatment was well tolerated, with no adverse effects observed, thereby passing the initial safety assessment.

Early signs of efficacy are encouraging. The patient will continue to be monitored in accordance with the FDA-approved clinical protocol to evaluate whether the secondary endpoints of the trial are achieved.

Manufacturing of HG-CT-1 is currently underway for the treatment of a second patient.

This Phase I clinical trial is a dose-escalation study designed to evaluate the safety profile of HG-CT-1 in adult patients with R/R AML. In addition to safety, key secondary objectives of the trial include:

• Assessing the efficacy of HG-CT-1 based on AML-specific response criteria
• Evaluating overall survival
• Measuring progression-free survival
• Determining duration of response in patients demonstrating clinical benefit

Data related to these secondary endpoints, including efficacy, durability, and overall clinical outcomes, will be collected over time through continued follow-up of the treated patient. These secondary endpoints are critical for assessing the potential clinical impact of HG-CT-1 in a patient population with limited remaining treatment options.

Further updates on the clinical trial will be provided in due course.

Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:

"The successful treatment of the first patient with HG-CT-1 marks a major milestone not only for Hemogenyx Pharmaceuticals but also for patients battling relapsed or refractory AML. We are encouraged by the favorable safety profile observed so far and the early signs of efficacy. This outcome strengthens our confidence in the potential of HG-CT-1 to address one of the most challenging and deadly forms of leukemia. We remain committed to advancing this therapy through clinical development with the goal of delivering a transformative treatment to patients in desperate need while creating long-term value for our shareholders."